Cardio- and cerebrovascular risk with conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS) in rheumatic arthritis (RA): a real-world comparative assesment

Documenti analoghi

• Is Farming a Risk Occupation for Cardio-cerebrovascular Diseases? A Scoping Review on Cardio-cerebrovascular Disease Risk in Farmers
  di: Hyeonjun Kim, et al.
  Pubblicazione: (2024-11-01)
• VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs
  di: David Schub, et al.
  Pubblicazione: (2018-11-01)
• Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study
  di: Naoki Iwamoto, et al.
  Pubblicazione: (2022-12-01)
• Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from ra-beyond up to 7 years of treatment
  di: Caporali, R, et al.
  Pubblicazione: (2022)
• Mg alloy cardio-/cerebrovascular scaffolds: Developments and prospects
  di: Shaokang Guan, et al.
  Pubblicazione: (2023-11-01)